

Bharat Biotech receives DCGI approval for Ph 3 trial of COVID-19 vaccine

23 October 2020 | News

The phase 3 trial will be conducted in 26,000 participants in over 25 centres across India



After successful completion of the interim analysis from the Phase 1 & 2 clinical trials of COVAXIN, Hyderabad based Bharat Biotech has received DCGI approval for Phase 3 clinical trials.

The phase 3 trial will be conducted in 26,000 participants in over 25 centres across India.

COVAXIN, India's indigenous COVID-19 vaccine by Bharat Biotech is developed in collaboration with the Indian Council of Medical Research (ICMR) - National Institute of Virology (NIV). The indigenous, inactivated vaccine is developed and manufactured in Bharat Biotech's BSL-3 (Bio-Safety Level 3) high containment facility.